CU Anschutz | Innovations continues its research focused on preventing relapse, targeting treatment-resistant cancer cells, and developing more effective and better-tolerated therapies.
Published
Signal category
Strategy & Corporate Development
Quote
“That collaborative approach has already helped advance breakthroughs like venetoclax for AML and continues today through research focused on preventing relapse, targeting treatment-resistant cancer cells, and developing more effective and better-tolerated therapies.”
— CU Anschutz | Innovations team
Company
CU Anschutz | Innovations
Biomedical Technology Licensing and Commercialization | Funding Resources | Healthcare Industry Partnerships
- Industry
- Higher Education
- Location
- Aurora, US
- Company size
- 52 employees
CU Anschutz | Innovations brings together industry partners, entrepreneurs, and investors to help CU Researchers solve important problems and improve the quality of life worldwide. With expertise in patents, copyrights, and licensing, we help translate discovery into impact through transparent, flexible, best practice intellectual property management services. We connect medical researchers at CU Anschutz with a variety of commercialization programs in the university and the community.